In prostate tumours, Torrano et al. demonstrated that higher expression of PPARGC1A - a key transcriptional co-regulator that activates expression of genes involved in oxidative metabolism – was associated with favourable prognosis [39]. This evidence concerns the gene PPARGC1A and prostate neoplasm.